Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 5fe81b1a-cc31-444e-a0f1-1ea4f7334b89

Humira

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2025-12-23
Captured
2026-09-09T23:37:51.659493+00:00
Current indication reconciliation
Not reconciled
Boxed warning in this label
  1. WARNING: SERIOUS INFECTIONS AND MALIGNANCY SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HUMIRA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HUMIRA use and during therapy. Initiate treatment for latent TB prior to HUMIRA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA [see Warnings and Precautions ( 5.2 )]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 )]. WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue HUMIRA if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting HUMIRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including HUMIRA.

Indications and usage: exact source text

  1. 1 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HUMIRA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. Limitations of Use The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 , 14.8 ) ] . 1.7 Plaque Psoriasis HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ] . 1.8 Hidradenitis Suppurativa HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
Full extracted label fields
application numbers
  1. BLA125057
boxed warning exact
  1. WARNING: SERIOUS INFECTIONS AND MALIGNANCY SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HUMIRA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HUMIRA use and during therapy. Initiate treatment for latent TB prior to HUMIRA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral and other infections due to opportunistic pathogens, including Legionella and Listeria. Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )]. MALIGNANCY Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA [see Warnings and Precautions ( 5.2 )]. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all these patients had received treatment with azathioprine or 6-mercaptopurine (6–MP) concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants [see Warnings and Precautions ( 5.2 )]. WARNING: SERIOUS INFECTIONS AND MALIGNANCY See full prescribing information for complete boxed warning. SERIOUS INFECTIONS ( 5.1 , 6.1 ): Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. Discontinue HUMIRA if a patient develops a serious infection or sepsis during treatment. Perform test for latent TB; if positive, start treatment for TB prior to starting HUMIRA. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. MALIGNANCY ( 5.2 ): Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including HUMIRA.
brand names
  1. Humira
current indication status
not_reconciled
dailymed set url
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4977567e-3525-44ac-9ff5-f1e74b053950
generic names
  1. ADALIMUMAB
id
5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
indications and usage exact
  1. 1 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HUMIRA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. Limitations of Use The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 , 14.8 ) ] . 1.7 Plaque Psoriasis HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ] . 1.8 Hidradenitis Suppurativa HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
indications and usage tables exact
    is original packager
    1. true
    manufacturer names
    1. Cordavis Limited
    matched search terms
    1. tumor
    package ndcs
    1. 83457-554-02
    2. 83457-553-01
    3. 83457-927-01
    4. 83457-124-02
    5. 83457-123-01
    6. 83457-243-02
    7. 83457-242-01
    8. 83457-616-02
    9. 83457-615-01
    10. 83457-817-02
    11. 83457-816-01
    product ndcs
    1. 83457-124
    2. 83457-554
    3. 83457-243
    4. 83457-616
    5. 83457-817
    product types
    1. HUMAN PRESCRIPTION DRUG
    recent major changes exact
    1. Warnings and Precautions, Autoimmunity ( 5.9 ) 7/2025
    record type
    complete_spl_indications_section_candidate
    routes
      rxcuis
      1. 797544
      2. 1726844
      3. 1726846
      4. 1872979
      5. 1872980
      6. 1921009
      7. 1921010
      8. 1921016
      9. 1921017
      10. 1921238
      11. 1921240
      source batch
      file
      /private/tmp/cancer-full-research/indications/raw/labels-00400.json
      meta
      disclaimer
      Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
      last updated
      2026-09-09
      results
      limit
      100
      skip
      400
      total
      830
      sha256
      a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
      url
      https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=400&sort=id%3Aasc
      source url
      https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
      spl effective date
      2025-12-23
      spl effective time
      20251223
      spl set id
      4977567e-3525-44ac-9ff5-f1e74b053950
      spl version
      4
      substance names
        uniis
          verification flags
          1. oncology_keyword_candidate_not_clinically_classified
          2. spl_text_not_verified_identical_to_latest_approved_label
          3. individual_indications_not_split_or_reconciled
          4. fda_label_posted_after_spl_effective_date_requires_version_review
          Drugs@FDA application source records
          1. application number
            BLA125057
            payload
            all indexed label documents
            1. Appl No
              125057
              Application Docs Date
              2005-10-10 00:00:00
              Application Docs ID
              18746
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              45
              Submission Type
              SUPPL
            2. Appl No
              125057
              Application Docs Date
              2006-11-14 00:00:00
              Application Docs ID
              18747
              Application Docs Title
              0
              Application Docs Type ID
              2
              Application Docs URL
              http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s071, s095LBL.pdf
              Submission No
              71
              Submission Type
              SUPPL
            3. Appl No
              125057
              Application Docs Date
              2007-07-31 00:00:00
              Application Docs ID
              18748
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              94
              Submission Type
              SUPPL
            4. Appl No
              125057
              Application Docs Date
              2006-11-14 00:00:00
              Application Docs ID
              18749
              Application Docs Title
              0
              Application Docs Type ID
              2
              Application Docs URL
              http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125057s071, s095LBL.pdf
              Submission No
              95
              Submission Type
              SUPPL
            5. Appl No
              125057
              Application Docs Date
              2008-02-26 00:00:00
              Application Docs ID
              18750
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              114
              Submission Type
              SUPPL
            6. Appl No
              125057
              Application Docs Date
              2011-03-04 00:00:00
              Application Docs ID
              18751
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              215
              Submission Type
              SUPPL
            7. Appl No
              125057
              Application Docs Date
              2012-05-29 00:00:00
              Application Docs ID
              18752
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              278
              Submission Type
              SUPPL
            8. Appl No
              125057
              Application Docs Date
              2013-05-13 00:00:00
              Application Docs ID
              18753
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              310
              Submission Type
              SUPPL
            9. Appl No
              125057
              Application Docs Date
              2013-04-29 00:00:00
              Application Docs ID
              18754
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              322
              Submission Type
              SUPPL
            10. Appl No
              125057
              Application Docs Date
              2013-09-24 00:00:00
              Application Docs ID
              18755
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              327
              Submission Type
              SUPPL
            11. Appl No
              125057
              Application Docs Date
              2014-09-26 00:00:00
              Application Docs ID
              18756
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              356
              Submission Type
              SUPPL
            12. Appl No
              125057
              Application Docs Date
              2014-06-03 00:00:00
              Application Docs ID
              18757
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              366
              Submission Type
              SUPPL
            all submission records
            1. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              322
              Submission Status
              AP
              Submission Status Date
              2013-04-24 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            2. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              327
              Submission Status
              AP
              Submission Status Date
              2013-09-19 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            3. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              355
              Submission Status
              AP
              Submission Status Date
              2014-02-26 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            4. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              2
              Submission No
              356
              Submission Status
              AP
              Submission Status Date
              2014-09-23 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            5. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              366
              Submission Status
              AP
              Submission Status Date
              2014-05-30 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            6. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              2
              Submission No
              367
              Submission Status
              AP
              Submission Status Date
              2014-09-30 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            7. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              368
              Submission Status
              AP
              Submission Status Date
              2014-05-14 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            8. Appl No
              125057
              Review Priority
              Submission Class Code ID
              4
              Submission No
              381
              Submission Status
              AP
              Submission Status Date
              2014-08-07 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            9. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              384
              Submission Status
              AP
              Submission Status Date
              2014-10-29 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            10. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              3
              Submission No
              390
              Submission Status
              AP
              Submission Status Date
              2014-11-06 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            11. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              2
              Submission No
              393
              Submission Status
              AP
              Submission Status Date
              2015-09-09 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            12. Appl No
              125057
              Review Priority
              STANDARD
              Submission Class Code ID
              2
              Submission No
              394
              Submission Status
              AP
              Submission Status Date
              2015-11-23 00:00:00
              Submission Type
              SUPPL
              Submissions Public Notes
            application number
            BLA125057
            approval interpretation
            Application linkage and approved submission are not indication-level current approval verification
            current indication status
            not_reconciled
            has approved submission record
            true
            latest approved submission date
            2025-12-23
            latest label selection rule
            max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
            latest posted label documents
            1. Appl No
              125057
              Application Docs Date
              2026-01-06 00:00:00
              Application Docs ID
              84663
              Application Docs Title
              0
              Application Docs Type ID
              2
              Submission No
              425
              Submission Type
              SUPPL
            official application record
            Appl No
            125057
            Appl Public Notes
            Appl Type
            BLA
            Sponsor Name
            ABBVIE INC
            openfda application present
            true
            products
            1. Active Ingredient
              ADALIMUMAB
              Appl No
              125057
              Drug Name
              HUMIRA
              Form
              SYRINGE
              Product No
              001
              Reference Drug
              0
              Reference Standard
              Strength
              40MG/0.8ML
              marketing status
              1. Prescription
            2. Active Ingredient
              ADALIMUMAB
              Appl No
              125057
              Drug Name
              HUMIRA
              Form
              VIAL
              Product No
              002
              Reference Drug
              0
              Reference Standard
              Strength
              40MG/0.8ML
              marketing status
              1. Prescription

          Source passages and status connections

          Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

          Passage 1 · positive indication candidate
          application numbers
          1. BLA125057
          brand names
          1. Humira
          classification reasons
          1. explicit_positive_indication_predicate
          2. tumor_or_malignant_hematology_words_in_positive_statement
          clinical review status
          pending
          content role
          positive_indication_candidate
          context span
          end
          508
          end exclusive
          true
          exact text
          1 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting
          label id
          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
          start
          0
          current approval status
          not_reconciled
          duplicate text group
          dup-b71919a5199b9a42dc76
          extraction review status
          automated_candidate_pending_source_review
          generic names
          1. ADALIMUMAB
          id
          ind-span-16d57a97a5183574d52f
          label id
          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
          positive predicate support span
          end
          81
          end exclusive
          true
          exact text
          is a tumor necrosis factor (TNF) blocker indicated
          label id
          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
          offset unit
          unicode_code_points
          source array index
          0
          source field
          indications_and_usage_exact
          source text sha256
          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
          start
          31
          qualifier mentions
          1. context exact
            on of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis .
            kind
            age
            polarity
            not_inferred
            span
            end
            248
            end exclusive
            true
            exact text
            adult patients
            label id
            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
            offset unit
            unicode_code_points
            source array index
            0
            source field
            indications_and_usage_exact
            source text sha256
            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
            start
            234
          regulatory links
            schema version
            0.1.0
            source batch sha256
            a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
            source defined aliases
              source span
              end
              308
              end exclusive
              true
              exact text
              1 INDICATIONS AND USAGE HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis .
              label id
              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
              start
              0
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
              spl effective date
              2025-12-23
              spl set id
              4977567e-3525-44ac-9ff5-f1e74b053950
              spl version
              4
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              tumor_directed_candidate
              Passage 2 · unclassified context
              application numbers
              1. BLA125057
              brand names
              1. Humira
              classification reasons
              1. no_unambiguous_positive_indication_predicate
              clinical review status
              pending
              content role
              unclassified_context
              context span
              end
              659
              end exclusive
              true
              exact text
              ptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and sy
              label id
              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
              start
              109
              current approval status
              not_reconciled
              duplicate text group
              dup-6f91ceb5490f4b5f4652
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. ADALIMUMAB
              id
              ind-span-bb5b684ad0f981e373db
              label id
              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
              positive predicate support span
              Source null
              qualifier mentions
              1. context exact
                ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
                kind
                age
                polarity
                not_inferred
                span
                end
                448
                end exclusive
                true
                exact text
                2 years of age
                label id
                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                offset unit
                unicode_code_points
                source array index
                0
                source field
                indications_and_usage_exact
                source text sha256
                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                start
                434
              regulatory links
                schema version
                0.1.0
                source batch sha256
                a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                source defined aliases
                  source span
                  end
                  459
                  end exclusive
                  true
                  exact text
                  ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
                  label id
                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                  start
                  309
                  source url
                  https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                  spl effective date
                  2025-12-23
                  spl set id
                  4977567e-3525-44ac-9ff5-f1e74b053950
                  spl version
                  4
                  structured fields status
                  not_extracted_no_values_inferred_from_mentions
                  structured indication
                  age
                  Source null
                  approval pathway
                  Source null
                  biomarker and test
                  Source null
                  disease stage
                  Source null
                  limitations
                  Source null
                  line
                  Source null
                  prior therapy
                  Source null
                  regimen
                  Source null
                  tumor histology
                  Source null
                  use intent
                  unclear
                  Passage 3 · positive indication candidate
                  application numbers
                  1. BLA125057
                  brand names
                  1. Humira
                  classification reasons
                  1. inherited_predicate_from_same_label_section_requires_review
                  2. no_tumor_directed_keyword_in_positive_statement
                  clinical review status
                  pending
                  content role
                  positive_indication_candidate
                  context span
                  end
                  829
                  end exclusive
                  true
                  exact text
                  tely to severely active r heumatoid a rthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years
                  label id
                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                  start
                  260
                  current approval status
                  not_reconciled
                  duplicate text group
                  dup-73fc98fce086d21cce52
                  extraction review status
                  automated_candidate_pending_source_review
                  generic names
                  1. ADALIMUMAB
                  id
                  ind-span-7d9ce9a2c33252cac231
                  label id
                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                  positive predicate support span
                  end
                  81
                  end exclusive
                  true
                  exact text
                  is a tumor necrosis factor (TNF) blocker indicated
                  label id
                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                  offset unit
                  unicode_code_points
                  source array index
                  0
                  source field
                  indications_and_usage_exact
                  source text sha256
                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                  start
                  31
                  qualifier mentions
                  1. context exact
                    on of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
                    kind
                    age
                    polarity
                    not_inferred
                    span
                    end
                    595
                    end exclusive
                    true
                    exact text
                    adult patients
                    label id
                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                    start
                    581
                  regulatory links
                    schema version
                    0.1.0
                    source batch sha256
                    a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                    source defined aliases
                      source span
                      end
                      629
                      end exclusive
                      true
                      exact text
                      ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis .
                      label id
                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                      start
                      460
                      source url
                      https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                      spl effective date
                      2025-12-23
                      spl set id
                      4977567e-3525-44ac-9ff5-f1e74b053950
                      spl version
                      4
                      structured fields status
                      not_extracted_no_values_inferred_from_mentions
                      structured indication
                      age
                      Source null
                      approval pathway
                      Source null
                      biomarker and test
                      Source null
                      disease stage
                      Source null
                      limitations
                      Source null
                      line
                      Source null
                      prior therapy
                      Source null
                      regimen
                      Source null
                      tumor histology
                      Source null
                      use intent
                      non_oncology_or_unclear_candidate
                      Passage 4 · positive indication candidate
                      application numbers
                      1. BLA125057
                      brand names
                      1. Humira
                      classification reasons
                      1. inherited_predicate_from_same_label_section_requires_review
                      2. no_tumor_directed_keyword_in_positive_statement
                      clinical review status
                      pending
                      content role
                      positive_indication_candidate
                      context span
                      end
                      920
                      end exclusive
                      true
                      exact text
                      nts 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in
                      label id
                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                      start
                      430
                      current approval status
                      not_reconciled
                      duplicate text group
                      dup-1c036fb1efbd43891f58
                      extraction review status
                      automated_candidate_pending_source_review
                      generic names
                      1. ADALIMUMAB
                      id
                      ind-span-fd874564095aafcd50ed
                      label id
                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                      positive predicate support span
                      end
                      81
                      end exclusive
                      true
                      exact text
                      is a tumor necrosis factor (TNF) blocker indicated
                      label id
                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                      offset unit
                      unicode_code_points
                      source array index
                      0
                      source field
                      indications_and_usage_exact
                      source text sha256
                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                      start
                      31
                      qualifier mentions
                      1. context exact
                        ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
                        kind
                        age
                        polarity
                        not_inferred
                        span
                        end
                        683
                        end exclusive
                        true
                        exact text
                        adult patients
                        label id
                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                        offset unit
                        unicode_code_points
                        source array index
                        0
                        source field
                        indications_and_usage_exact
                        source text sha256
                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                        start
                        669
                      regulatory links
                        schema version
                        0.1.0
                        source batch sha256
                        a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                        source defined aliases
                          source span
                          end
                          720
                          end exclusive
                          true
                          exact text
                          ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis .
                          label id
                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                          start
                          630
                          source url
                          https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                          spl effective date
                          2025-12-23
                          spl set id
                          4977567e-3525-44ac-9ff5-f1e74b053950
                          spl version
                          4
                          structured fields status
                          not_extracted_no_values_inferred_from_mentions
                          structured indication
                          age
                          Source null
                          approval pathway
                          Source null
                          biomarker and test
                          Source null
                          disease stage
                          Source null
                          limitations
                          Source null
                          line
                          Source null
                          prior therapy
                          Source null
                          regimen
                          Source null
                          tumor histology
                          Source null
                          use intent
                          non_oncology_or_unclear_candidate
                          Passage 5 · positive indication candidate
                          application numbers
                          1. BLA125057
                          brand names
                          1. Humira
                          classification reasons
                          1. inherited_predicate_from_same_label_section_requires_review
                          2. no_tumor_directed_keyword_in_positive_statement
                          clinical review status
                          pending
                          content role
                          positive_indication_candidate
                          context span
                          end
                          1046
                          end exclusive
                          true
                          exact text
                          on of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. ( 1.6 ) Limitations of Use: Effectiveness has not been established in
                          label id
                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                          start
                          521
                          current approval status
                          not_reconciled
                          duplicate text group
                          dup-f248a591c0455ce6b503
                          extraction review status
                          automated_candidate_pending_source_review
                          generic names
                          1. ADALIMUMAB
                          id
                          ind-span-e596cbeb49bb248d6c86
                          label id
                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                          positive predicate support span
                          end
                          81
                          end exclusive
                          true
                          exact text
                          is a tumor necrosis factor (TNF) blocker indicated
                          label id
                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                          start
                          31
                          qualifier mentions
                          1. context exact
                            eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                            kind
                            age
                            polarity
                            not_inferred
                            span
                            end
                            797
                            end exclusive
                            true
                            exact text
                            adults
                            label id
                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                            start
                            791
                          2. context exact
                            moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                            kind
                            age
                            polarity
                            not_inferred
                            span
                            end
                            820
                            end exclusive
                            true
                            exact text
                            pediatric patients
                            label id
                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                            start
                            802
                          3. context exact
                            ely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                            kind
                            age
                            polarity
                            not_inferred
                            span
                            end
                            835
                            end exclusive
                            true
                            exact text
                            6 years of age
                            label id
                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                            offset unit
                            unicode_code_points
                            source array index
                            0
                            source field
                            indications_and_usage_exact
                            source text sha256
                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                            start
                            821
                          regulatory links
                            schema version
                            0.1.0
                            source batch sha256
                            a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                            source defined aliases
                              source span
                              end
                              846
                              end exclusive
                              true
                              exact text
                              ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                              label id
                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                              start
                              721
                              source url
                              https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                              spl effective date
                              2025-12-23
                              spl set id
                              4977567e-3525-44ac-9ff5-f1e74b053950
                              spl version
                              4
                              structured fields status
                              not_extracted_no_values_inferred_from_mentions
                              structured indication
                              age
                              Source null
                              approval pathway
                              Source null
                              biomarker and test
                              Source null
                              disease stage
                              Source null
                              limitations
                              Source null
                              line
                              Source null
                              prior therapy
                              Source null
                              regimen
                              Source null
                              tumor histology
                              Source null
                              use intent
                              non_oncology_or_unclear_candidate
                              Passage 6 · unclassified context
                              application numbers
                              1. BLA125057
                              brand names
                              1. Humira
                              classification reasons
                              1. no_unambiguous_positive_indication_predicate
                              clinical review status
                              pending
                              content role
                              unclassified_context
                              context span
                              end
                              1175
                              end exclusive
                              true
                              exact text
                              signs and symptoms in adult patients with active ankylosing spondylitis . ( 1.4 ) Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chroni
                              label id
                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                              offset unit
                              unicode_code_points
                              source array index
                              0
                              source field
                              indications_and_usage_exact
                              source text sha256
                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                              start
                              647
                              current approval status
                              not_reconciled
                              duplicate text group
                              dup-8a4daca2b8b5d6fb597f
                              extraction review status
                              automated_candidate_pending_source_review
                              generic names
                              1. ADALIMUMAB
                              id
                              ind-span-371eaa6f90c6cb1247e2
                              label id
                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                              positive predicate support span
                              Source null
                              qualifier mentions
                              1. context exact
                                ment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.
                                kind
                                age
                                polarity
                                not_inferred
                                span
                                end
                                926
                                end exclusive
                                true
                                exact text
                                adults
                                label id
                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                start
                                920
                              2. context exact
                                erately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.
                                kind
                                age
                                polarity
                                not_inferred
                                span
                                end
                                949
                                end exclusive
                                true
                                exact text
                                pediatric patients
                                label id
                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                start
                                931
                              3. context exact
                                active ulcerative colitis in adults and pediatric patients 5 years of age and older.
                                kind
                                age
                                polarity
                                not_inferred
                                span
                                end
                                964
                                end exclusive
                                true
                                exact text
                                5 years of age
                                label id
                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                start
                                950
                              regulatory links
                                schema version
                                0.1.0
                                source batch sha256
                                a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                source defined aliases
                                  source span
                                  end
                                  975
                                  end exclusive
                                  true
                                  exact text
                                  ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.
                                  label id
                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                  start
                                  847
                                  source url
                                  https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                  spl effective date
                                  2025-12-23
                                  spl set id
                                  4977567e-3525-44ac-9ff5-f1e74b053950
                                  spl version
                                  4
                                  structured fields status
                                  not_extracted_no_values_inferred_from_mentions
                                  structured indication
                                  age
                                  Source null
                                  approval pathway
                                  Source null
                                  biomarker and test
                                  Source null
                                  disease stage
                                  Source null
                                  limitations
                                  Source null
                                  line
                                  Source null
                                  prior therapy
                                  Source null
                                  regimen
                                  Source null
                                  tumor histology
                                  Source null
                                  use intent
                                  unclear
                                  Passage 7 · limitation of use
                                  application numbers
                                  1. BLA125057
                                  brand names
                                  1. Humira
                                  classification reasons
                                  1. negative_or_not_established_clause
                                  clinical review status
                                  pending
                                  content role
                                  limitation_of_use
                                  context span
                                  end
                                  1316
                                  end exclusive
                                  true
                                  exact text
                                  n’s disease in adults and pediatric patients 6 years of age and older. ( 1.5 ) Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                                  label id
                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                  start
                                  776
                                  current approval status
                                  not_reconciled
                                  duplicate text group
                                  dup-77c09af1c9a777e9fa52
                                  extraction review status
                                  automated_candidate_pending_source_review
                                  generic names
                                  1. ADALIMUMAB
                                  id
                                  ind-span-b6a5095c827e3bb9508f
                                  label id
                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                  positive predicate support span
                                  Source null
                                  qualifier mentions
                                    regulatory links
                                      schema version
                                      0.1.0
                                      source batch sha256
                                      a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                      source defined aliases
                                        source span
                                        end
                                        1116
                                        end exclusive
                                        true
                                        exact text
                                        ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
                                        label id
                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                        start
                                        976
                                        source url
                                        https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                        spl effective date
                                        2025-12-23
                                        spl set id
                                        4977567e-3525-44ac-9ff5-f1e74b053950
                                        spl version
                                        4
                                        structured fields status
                                        not_extracted_no_values_inferred_from_mentions
                                        structured indication
                                        age
                                        Source null
                                        approval pathway
                                        Source null
                                        biomarker and test
                                        Source null
                                        disease stage
                                        Source null
                                        limitations
                                        Source null
                                        line
                                        Source null
                                        prior therapy
                                        Source null
                                        regimen
                                        Source null
                                        tumor histology
                                        Source null
                                        use intent
                                        not_applicable
                                        Passage 8 · unclassified context
                                        application numbers
                                        1. BLA125057
                                        brand names
                                        1. Humira
                                        classification reasons
                                        1. no_unambiguous_positive_indication_predicate
                                        clinical review status
                                        pending
                                        content role
                                        unclassified_context
                                        context span
                                        end
                                        1516
                                        end exclusive
                                        true
                                        exact text
                                        in adults and pediatric patients 5 years of age and older. ( 1.6 ) Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pedia
                                        label id
                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                        offset unit
                                        unicode_code_points
                                        source array index
                                        0
                                        source field
                                        indications_and_usage_exact
                                        source text sha256
                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                        start
                                        917
                                        current approval status
                                        not_reconciled
                                        duplicate text group
                                        dup-4e253e55e3c5477ca451
                                        extraction review status
                                        automated_candidate_pending_source_review
                                        generic names
                                        1. ADALIMUMAB
                                        id
                                        ind-span-18e40e65780f95f81014
                                        label id
                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                        positive predicate support span
                                        Source null
                                        qualifier mentions
                                        1. context exact
                                          Treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
                                          kind
                                          age
                                          polarity
                                          not_inferred
                                          span
                                          end
                                          1144
                                          end exclusive
                                          true
                                          exact text
                                          adult patients
                                          label id
                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                          start
                                          1130
                                        regulatory links
                                          schema version
                                          0.1.0
                                          source batch sha256
                                          a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                          source defined aliases
                                            source span
                                            end
                                            1316
                                            end exclusive
                                            true
                                            exact text
                                            Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                                            label id
                                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                            start
                                            1117
                                            source url
                                            https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                            spl effective date
                                            2025-12-23
                                            spl set id
                                            4977567e-3525-44ac-9ff5-f1e74b053950
                                            spl version
                                            4
                                            structured fields status
                                            not_extracted_no_values_inferred_from_mentions
                                            structured indication
                                            age
                                            Source null
                                            approval pathway
                                            Source null
                                            biomarker and test
                                            Source null
                                            disease stage
                                            Source null
                                            limitations
                                            Source null
                                            line
                                            Source null
                                            prior therapy
                                            Source null
                                            regimen
                                            Source null
                                            tumor histology
                                            Source null
                                            use intent
                                            unclear
                                            Passage 9 · unclassified context
                                            application numbers
                                            1. BLA125057
                                            brand names
                                            1. Humira
                                            classification reasons
                                            1. no_unambiguous_positive_indication_predicate
                                            clinical review status
                                            pending
                                            content role
                                            unclassified_context
                                            context span
                                            end
                                            1620
                                            end exclusive
                                            true
                                            exact text
                                            Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis HUMIRA is indicated for reducin
                                            label id
                                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                            offset unit
                                            unicode_code_points
                                            source array index
                                            0
                                            source field
                                            indications_and_usage_exact
                                            source text sha256
                                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                            start
                                            1117
                                            current approval status
                                            not_reconciled
                                            duplicate text group
                                            dup-678c0b39cca8319260cf
                                            extraction review status
                                            automated_candidate_pending_source_review
                                            generic names
                                            1. ADALIMUMAB
                                            id
                                            ind-span-dc2d64d6ac9bba8fb02d
                                            label id
                                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                            positive predicate support span
                                            Source null
                                            qualifier mentions
                                            1. context exact
                                              of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
                                              kind
                                              age
                                              polarity
                                              not_inferred
                                              span
                                              end
                                              1409
                                              end exclusive
                                              true
                                              exact text
                                              12 years of age
                                              label id
                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                              offset unit
                                              unicode_code_points
                                              source array index
                                              0
                                              source field
                                              indications_and_usage_exact
                                              source text sha256
                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                              start
                                              1394
                                            regulatory links
                                              schema version
                                              0.1.0
                                              source batch sha256
                                              a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                              source defined aliases
                                                source span
                                                end
                                                1420
                                                end exclusive
                                                true
                                                exact text
                                                ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
                                                label id
                                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                start
                                                1317
                                                source url
                                                https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                spl effective date
                                                2025-12-23
                                                spl set id
                                                4977567e-3525-44ac-9ff5-f1e74b053950
                                                spl version
                                                4
                                                structured fields status
                                                not_extracted_no_values_inferred_from_mentions
                                                structured indication
                                                age
                                                Source null
                                                approval pathway
                                                Source null
                                                biomarker and test
                                                Source null
                                                disease stage
                                                Source null
                                                limitations
                                                Source null
                                                line
                                                Source null
                                                prior therapy
                                                Source null
                                                regimen
                                                Source null
                                                tumor histology
                                                Source null
                                                use intent
                                                unclear
                                                Passage 10 · unclassified context
                                                application numbers
                                                1. BLA125057
                                                brand names
                                                1. Humira
                                                classification reasons
                                                1. no_unambiguous_positive_indication_predicate
                                                clinical review status
                                                pending
                                                content role
                                                unclassified_context
                                                context span
                                                end
                                                1755
                                                end exclusive
                                                true
                                                exact text
                                                emic therapy or phototherapy, and when other systemic therapies are medically less appropriate. ( 1.7 ) Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical functio
                                                label id
                                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                start
                                                1221
                                                current approval status
                                                not_reconciled
                                                duplicate text group
                                                dup-cff9f2a3c87782a9613b
                                                extraction review status
                                                automated_candidate_pending_source_review
                                                generic names
                                                1. ADALIMUMAB
                                                id
                                                ind-span-ead887af59a36d28b9a3
                                                label id
                                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                positive predicate support span
                                                Source null
                                                qualifier mentions
                                                1. context exact
                                                  f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                  kind
                                                  age
                                                  polarity
                                                  not_inferred
                                                  span
                                                  end
                                                  1506
                                                  end exclusive
                                                  true
                                                  exact text
                                                  adults
                                                  label id
                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                  start
                                                  1500
                                                2. context exact
                                                  tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                  kind
                                                  age
                                                  polarity
                                                  not_inferred
                                                  span
                                                  end
                                                  1529
                                                  end exclusive
                                                  true
                                                  exact text
                                                  pediatric patients
                                                  label id
                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                  start
                                                  1511
                                                3. context exact
                                                  posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                  kind
                                                  age
                                                  polarity
                                                  not_inferred
                                                  span
                                                  end
                                                  1544
                                                  end exclusive
                                                  true
                                                  exact text
                                                  2 years of age
                                                  label id
                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                  start
                                                  1530
                                                regulatory links
                                                  schema version
                                                  0.1.0
                                                  source batch sha256
                                                  a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                  source defined aliases
                                                    source span
                                                    end
                                                    1555
                                                    end exclusive
                                                    true
                                                    exact text
                                                    ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                    label id
                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                    start
                                                    1421
                                                    source url
                                                    https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                    spl effective date
                                                    2025-12-23
                                                    spl set id
                                                    4977567e-3525-44ac-9ff5-f1e74b053950
                                                    spl version
                                                    4
                                                    structured fields status
                                                    not_extracted_no_values_inferred_from_mentions
                                                    structured indication
                                                    age
                                                    Source null
                                                    approval pathway
                                                    Source null
                                                    biomarker and test
                                                    Source null
                                                    disease stage
                                                    Source null
                                                    limitations
                                                    Source null
                                                    line
                                                    Source null
                                                    prior therapy
                                                    Source null
                                                    regimen
                                                    Source null
                                                    tumor histology
                                                    Source null
                                                    use intent
                                                    unclear
                                                    Passage 11 · unclassified context
                                                    application numbers
                                                    1. BLA125057
                                                    brand names
                                                    1. Humira
                                                    classification reasons
                                                    1. no_unambiguous_positive_indication_predicate
                                                    clinical review status
                                                    pending
                                                    content role
                                                    unclassified_context
                                                    context span
                                                    end
                                                    1763
                                                    end exclusive
                                                    true
                                                    exact text
                                                    hidradenitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adu
                                                    label id
                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                    start
                                                    1356
                                                    current approval status
                                                    not_reconciled
                                                    duplicate text group
                                                    dup-45340efcf894f25e916f
                                                    extraction review status
                                                    automated_candidate_pending_source_review
                                                    generic names
                                                    1. ADALIMUMAB
                                                    id
                                                    ind-span-f52865daf43fcf204aca
                                                    label id
                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                    positive predicate support span
                                                    Source null
                                                    qualifier mentions
                                                      regulatory links
                                                        schema version
                                                        0.1.0
                                                        source batch sha256
                                                        a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                        source defined aliases
                                                          source span
                                                          end
                                                          1563
                                                          end exclusive
                                                          true
                                                          exact text
                                                          ( 1.9 )
                                                          label id
                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                          start
                                                          1556
                                                          source url
                                                          https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                          spl effective date
                                                          2025-12-23
                                                          spl set id
                                                          4977567e-3525-44ac-9ff5-f1e74b053950
                                                          spl version
                                                          4
                                                          structured fields status
                                                          not_extracted_no_values_inferred_from_mentions
                                                          structured indication
                                                          age
                                                          Source null
                                                          approval pathway
                                                          Source null
                                                          biomarker and test
                                                          Source null
                                                          disease stage
                                                          Source null
                                                          limitations
                                                          Source null
                                                          line
                                                          Source null
                                                          prior therapy
                                                          Source null
                                                          regimen
                                                          Source null
                                                          tumor histology
                                                          Source null
                                                          use intent
                                                          unclear
                                                          Passage 12 · positive indication candidate
                                                          application numbers
                                                          1. BLA125057
                                                          brand names
                                                          1. Humira
                                                          classification reasons
                                                          1. explicit_positive_indication_predicate
                                                          2. no_tumor_directed_keyword_in_positive_statement
                                                          clinical review status
                                                          pending
                                                          content role
                                                          positive_indication_candidate
                                                          context span
                                                          end
                                                          2031
                                                          end exclusive
                                                          true
                                                          exact text
                                                          nitis suppurativa in patients 12 years of age and older. ( 1.8 ) Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older. ( 1.9 ) 1.1 Rheumatoid Arthritis HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing
                                                          label id
                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                          start
                                                          1364
                                                          current approval status
                                                          not_reconciled
                                                          duplicate text group
                                                          dup-cc98b108a48a3233cf8e
                                                          extraction review status
                                                          automated_candidate_pending_source_review
                                                          generic names
                                                          1. ADALIMUMAB
                                                          id
                                                          ind-span-def4a16dc3504a64280e
                                                          label id
                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                          positive predicate support span
                                                          end
                                                          1608
                                                          end exclusive
                                                          true
                                                          exact text
                                                          is indicated
                                                          label id
                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                          start
                                                          1596
                                                          qualifier mentions
                                                          1. context exact
                                                            on of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
                                                            kind
                                                            age
                                                            polarity
                                                            not_inferred
                                                            span
                                                            end
                                                            1774
                                                            end exclusive
                                                            true
                                                            exact text
                                                            adult patients
                                                            label id
                                                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                            offset unit
                                                            unicode_code_points
                                                            source array index
                                                            0
                                                            source field
                                                            indications_and_usage_exact
                                                            source text sha256
                                                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                            start
                                                            1760
                                                          regulatory links
                                                            schema version
                                                            0.1.0
                                                            source batch sha256
                                                            a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                            source defined aliases
                                                              source span
                                                              end
                                                              1831
                                                              end exclusive
                                                              true
                                                              exact text
                                                              1.1 Rheumatoid Arthritis HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
                                                              label id
                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                              start
                                                              1564
                                                              source url
                                                              https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                              spl effective date
                                                              2025-12-23
                                                              spl set id
                                                              4977567e-3525-44ac-9ff5-f1e74b053950
                                                              spl version
                                                              4
                                                              structured fields status
                                                              not_extracted_no_values_inferred_from_mentions
                                                              structured indication
                                                              age
                                                              Source null
                                                              approval pathway
                                                              Source null
                                                              biomarker and test
                                                              Source null
                                                              disease stage
                                                              Source null
                                                              limitations
                                                              Source null
                                                              line
                                                              Source null
                                                              prior therapy
                                                              Source null
                                                              regimen
                                                              Source null
                                                              tumor histology
                                                              Source null
                                                              use intent
                                                              non_oncology_or_unclear_candidate
                                                              Passage 13 · unclassified context
                                                              application numbers
                                                              1. BLA125057
                                                              brand names
                                                              1. Humira
                                                              classification reasons
                                                              1. no_unambiguous_positive_indication_predicate
                                                              clinical review status
                                                              pending
                                                              content role
                                                              unclassified_context
                                                              context span
                                                              end
                                                              2163
                                                              end exclusive
                                                              true
                                                              exact text
                                                              symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
                                                              label id
                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                              offset unit
                                                              unicode_code_points
                                                              source array index
                                                              0
                                                              source field
                                                              indications_and_usage_exact
                                                              source text sha256
                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                              start
                                                              1632
                                                              current approval status
                                                              not_reconciled
                                                              duplicate text group
                                                              dup-e9a88bfd8cf531fcff35
                                                              extraction review status
                                                              automated_candidate_pending_source_review
                                                              generic names
                                                              1. ADALIMUMAB
                                                              id
                                                              ind-span-62259b7faa987075ee34
                                                              label id
                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                              positive predicate support span
                                                              Source null
                                                              qualifier mentions
                                                              1. context exact
                                                                HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                                kind
                                                                biomarker
                                                                polarity
                                                                not_inferred
                                                                span
                                                                end
                                                                1923
                                                                end exclusive
                                                                true
                                                                exact text
                                                                methotrexate or other non-biologic disease-
                                                                label id
                                                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                start
                                                                1880
                                                              2. context exact
                                                                HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                                kind
                                                                regimen
                                                                polarity
                                                                not_inferred
                                                                span
                                                                end
                                                                1962
                                                                end exclusive
                                                                true
                                                                exact text
                                                                in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs)
                                                                label id
                                                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                start
                                                                1860
                                                              regulatory links
                                                                schema version
                                                                0.1.0
                                                                source batch sha256
                                                                a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                source defined aliases
                                                                  source span
                                                                  end
                                                                  1963
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs).
                                                                  label id
                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                  start
                                                                  1832
                                                                  source url
                                                                  https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                  spl effective date
                                                                  2025-12-23
                                                                  spl set id
                                                                  4977567e-3525-44ac-9ff5-f1e74b053950
                                                                  spl version
                                                                  4
                                                                  structured fields status
                                                                  not_extracted_no_values_inferred_from_mentions
                                                                  structured indication
                                                                  age
                                                                  Source null
                                                                  approval pathway
                                                                  Source null
                                                                  biomarker and test
                                                                  Source null
                                                                  disease stage
                                                                  Source null
                                                                  limitations
                                                                  Source null
                                                                  line
                                                                  Source null
                                                                  prior therapy
                                                                  Source null
                                                                  regimen
                                                                  Source null
                                                                  tumor histology
                                                                  Source null
                                                                  use intent
                                                                  unclear
                                                                  Passage 14 · positive indication candidate
                                                                  application numbers
                                                                  1. BLA125057
                                                                  brand names
                                                                  1. Humira
                                                                  classification reasons
                                                                  1. explicit_positive_indication_predicate
                                                                  2. no_tumor_directed_keyword_in_positive_statement
                                                                  clinical review status
                                                                  pending
                                                                  content role
                                                                  positive_indication_candidate
                                                                  context span
                                                                  end
                                                                  2364
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  t patients with moderately to severely active rheumatoid arthritis. HUMIRA can be used alone or in combination with methotrexate or other non-biologic disease-modifying anti-rheumatic drugs (DMARDs). 1.2 Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improvi
                                                                  label id
                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                  start
                                                                  1764
                                                                  current approval status
                                                                  not_reconciled
                                                                  duplicate text group
                                                                  dup-1a028d20908efd491370
                                                                  extraction review status
                                                                  automated_candidate_pending_source_review
                                                                  generic names
                                                                  1. ADALIMUMAB
                                                                  id
                                                                  ind-span-99a2ae8f55f845cf7828
                                                                  label id
                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                  positive predicate support span
                                                                  end
                                                                  2017
                                                                  end exclusive
                                                                  true
                                                                  exact text
                                                                  is indicated
                                                                  label id
                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                  offset unit
                                                                  unicode_code_points
                                                                  source array index
                                                                  0
                                                                  source field
                                                                  indications_and_usage_exact
                                                                  source text sha256
                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                  start
                                                                  2005
                                                                  qualifier mentions
                                                                  1. context exact
                                                                    ive polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
                                                                    kind
                                                                    age
                                                                    polarity
                                                                    not_inferred
                                                                    span
                                                                    end
                                                                    2153
                                                                    end exclusive
                                                                    true
                                                                    exact text
                                                                    2 years of age
                                                                    label id
                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                    offset unit
                                                                    unicode_code_points
                                                                    source array index
                                                                    0
                                                                    source field
                                                                    indications_and_usage_exact
                                                                    source text sha256
                                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                    start
                                                                    2139
                                                                  regulatory links
                                                                    schema version
                                                                    0.1.0
                                                                    source batch sha256
                                                                    a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                    source defined aliases
                                                                      source span
                                                                      end
                                                                      2164
                                                                      end exclusive
                                                                      true
                                                                      exact text
                                                                      1.2 Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
                                                                      label id
                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                      offset unit
                                                                      unicode_code_points
                                                                      source array index
                                                                      0
                                                                      source field
                                                                      indications_and_usage_exact
                                                                      source text sha256
                                                                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                      start
                                                                      1964
                                                                      source url
                                                                      https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                      spl effective date
                                                                      2025-12-23
                                                                      spl set id
                                                                      4977567e-3525-44ac-9ff5-f1e74b053950
                                                                      spl version
                                                                      4
                                                                      structured fields status
                                                                      not_extracted_no_values_inferred_from_mentions
                                                                      structured indication
                                                                      age
                                                                      Source null
                                                                      approval pathway
                                                                      Source null
                                                                      biomarker and test
                                                                      Source null
                                                                      disease stage
                                                                      Source null
                                                                      limitations
                                                                      Source null
                                                                      line
                                                                      Source null
                                                                      prior therapy
                                                                      Source null
                                                                      regimen
                                                                      Source null
                                                                      tumor histology
                                                                      Source null
                                                                      use intent
                                                                      non_oncology_or_unclear_candidate
                                                                      Passage 15 · unclassified context
                                                                      application numbers
                                                                      1. BLA125057
                                                                      brand names
                                                                      1. Humira
                                                                      classification reasons
                                                                      1. no_unambiguous_positive_indication_predicate
                                                                      clinical review status
                                                                      pending
                                                                      content role
                                                                      unclassified_context
                                                                      context span
                                                                      end
                                                                      2426
                                                                      end exclusive
                                                                      true
                                                                      exact text
                                                                      .2 Juvenile Idiopathic Arthritis HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic a
                                                                      label id
                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                      offset unit
                                                                      unicode_code_points
                                                                      source array index
                                                                      0
                                                                      source field
                                                                      indications_and_usage_exact
                                                                      source text sha256
                                                                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                      start
                                                                      1965
                                                                      current approval status
                                                                      not_reconciled
                                                                      duplicate text group
                                                                      dup-11720ba11a4d334c9a8b
                                                                      extraction review status
                                                                      automated_candidate_pending_source_review
                                                                      generic names
                                                                      1. ADALIMUMAB
                                                                      id
                                                                      ind-span-e6ff35fc821e5dcdf405
                                                                      label id
                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                      positive predicate support span
                                                                      Source null
                                                                      qualifier mentions
                                                                      1. context exact
                                                                        HUMIRA can be used alone or in combination with methotrexate.
                                                                        kind
                                                                        biomarker
                                                                        polarity
                                                                        not_inferred
                                                                        span
                                                                        end
                                                                        2225
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        methotrexate
                                                                        label id
                                                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                        start
                                                                        2213
                                                                      2. context exact
                                                                        HUMIRA can be used alone or in combination with methotrexate.
                                                                        kind
                                                                        regimen
                                                                        polarity
                                                                        not_inferred
                                                                        span
                                                                        end
                                                                        2225
                                                                        end exclusive
                                                                        true
                                                                        exact text
                                                                        in combination with methotrexate
                                                                        label id
                                                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                        offset unit
                                                                        unicode_code_points
                                                                        source array index
                                                                        0
                                                                        source field
                                                                        indications_and_usage_exact
                                                                        source text sha256
                                                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                        start
                                                                        2193
                                                                      regulatory links
                                                                        schema version
                                                                        0.1.0
                                                                        source batch sha256
                                                                        a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                        source defined aliases
                                                                          source span
                                                                          end
                                                                          2226
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          HUMIRA can be used alone or in combination with methotrexate.
                                                                          label id
                                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                          start
                                                                          2165
                                                                          source url
                                                                          https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                          spl effective date
                                                                          2025-12-23
                                                                          spl set id
                                                                          4977567e-3525-44ac-9ff5-f1e74b053950
                                                                          spl version
                                                                          4
                                                                          structured fields status
                                                                          not_extracted_no_values_inferred_from_mentions
                                                                          structured indication
                                                                          age
                                                                          Source null
                                                                          approval pathway
                                                                          Source null
                                                                          biomarker and test
                                                                          Source null
                                                                          disease stage
                                                                          Source null
                                                                          limitations
                                                                          Source null
                                                                          line
                                                                          Source null
                                                                          prior therapy
                                                                          Source null
                                                                          regimen
                                                                          Source null
                                                                          tumor histology
                                                                          Source null
                                                                          use intent
                                                                          unclear
                                                                          Passage 16 · positive indication candidate
                                                                          application numbers
                                                                          1. BLA125057
                                                                          brand names
                                                                          1. Humira
                                                                          classification reasons
                                                                          1. explicit_positive_indication_predicate
                                                                          2. no_tumor_directed_keyword_in_positive_statement
                                                                          clinical review status
                                                                          pending
                                                                          content role
                                                                          positive_indication_candidate
                                                                          context span
                                                                          end
                                                                          2635
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          ing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. HUMIRA can be used alone or in combination with methotrexate. 1.3 Psoriatic Arthritis HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HUMIRA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondyliti
                                                                          label id
                                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                          start
                                                                          2027
                                                                          current approval status
                                                                          not_reconciled
                                                                          duplicate text group
                                                                          dup-71e0d9cc70b35c789f4d
                                                                          extraction review status
                                                                          automated_candidate_pending_source_review
                                                                          generic names
                                                                          1. ADALIMUMAB
                                                                          id
                                                                          ind-span-ab198870a4cd14959ae8
                                                                          label id
                                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                          positive predicate support span
                                                                          end
                                                                          2270
                                                                          end exclusive
                                                                          true
                                                                          exact text
                                                                          is indicated
                                                                          label id
                                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                          offset unit
                                                                          unicode_code_points
                                                                          source array index
                                                                          0
                                                                          source field
                                                                          indications_and_usage_exact
                                                                          source text sha256
                                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                          start
                                                                          2258
                                                                          qualifier mentions
                                                                          1. context exact
                                                                            on of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
                                                                            kind
                                                                            age
                                                                            polarity
                                                                            not_inferred
                                                                            span
                                                                            end
                                                                            2402
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            adult patients
                                                                            label id
                                                                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                            start
                                                                            2388
                                                                          regulatory links
                                                                            schema version
                                                                            0.1.0
                                                                            source batch sha256
                                                                            a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                            source defined aliases
                                                                              source span
                                                                              end
                                                                              2435
                                                                              end exclusive
                                                                              true
                                                                              exact text
                                                                              1.3 Psoriatic Arthritis HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
                                                                              label id
                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                              offset unit
                                                                              unicode_code_points
                                                                              source array index
                                                                              0
                                                                              source field
                                                                              indications_and_usage_exact
                                                                              source text sha256
                                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                              start
                                                                              2227
                                                                              source url
                                                                              https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                              spl effective date
                                                                              2025-12-23
                                                                              spl set id
                                                                              4977567e-3525-44ac-9ff5-f1e74b053950
                                                                              spl version
                                                                              4
                                                                              structured fields status
                                                                              not_extracted_no_values_inferred_from_mentions
                                                                              structured indication
                                                                              age
                                                                              Source null
                                                                              approval pathway
                                                                              Source null
                                                                              biomarker and test
                                                                              Source null
                                                                              disease stage
                                                                              Source null
                                                                              limitations
                                                                              Source null
                                                                              line
                                                                              Source null
                                                                              prior therapy
                                                                              Source null
                                                                              regimen
                                                                              Source null
                                                                              tumor histology
                                                                              Source null
                                                                              use intent
                                                                              non_oncology_or_unclear_candidate
                                                                              Passage 17 · unclassified context
                                                                              application numbers
                                                                              1. BLA125057
                                                                              brand names
                                                                              1. Humira
                                                                              classification reasons
                                                                              1. no_unambiguous_positive_indication_predicate
                                                                              clinical review status
                                                                              pending
                                                                              content role
                                                                              unclassified_context
                                                                              context span
                                                                              end
                                                                              2704
                                                                              end exclusive
                                                                              true
                                                                              exact text
                                                                              atic Arthritis HUMIRA is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HUMIRA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HUMIRA is indicated for the treatment of moder
                                                                              label id
                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                              offset unit
                                                                              unicode_code_points
                                                                              source array index
                                                                              0
                                                                              source field
                                                                              indications_and_usage_exact
                                                                              source text sha256
                                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                              start
                                                                              2236
                                                                              current approval status
                                                                              not_reconciled
                                                                              duplicate text group
                                                                              dup-1539ee27d4ea4401740f
                                                                              extraction review status
                                                                              automated_candidate_pending_source_review
                                                                              generic names
                                                                              1. ADALIMUMAB
                                                                              id
                                                                              ind-span-460dee0054b079dfb5e5
                                                                              label id
                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                              positive predicate support span
                                                                              Source null
                                                                              qualifier mentions
                                                                              1. context exact
                                                                                HUMIRA can be used alone or in combination with non-biologic DMARDs.
                                                                                kind
                                                                                regimen
                                                                                polarity
                                                                                not_inferred
                                                                                span
                                                                                end
                                                                                2503
                                                                                end exclusive
                                                                                true
                                                                                exact text
                                                                                in combination with non-biologic DMARDs
                                                                                label id
                                                                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                offset unit
                                                                                unicode_code_points
                                                                                source array index
                                                                                0
                                                                                source field
                                                                                indications_and_usage_exact
                                                                                source text sha256
                                                                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                start
                                                                                2464
                                                                              regulatory links
                                                                                schema version
                                                                                0.1.0
                                                                                source batch sha256
                                                                                a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                source defined aliases
                                                                                  source span
                                                                                  end
                                                                                  2504
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  HUMIRA can be used alone or in combination with non-biologic DMARDs.
                                                                                  label id
                                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                  start
                                                                                  2436
                                                                                  source url
                                                                                  https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                  spl effective date
                                                                                  2025-12-23
                                                                                  spl set id
                                                                                  4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                  spl version
                                                                                  4
                                                                                  structured fields status
                                                                                  not_extracted_no_values_inferred_from_mentions
                                                                                  structured indication
                                                                                  age
                                                                                  Source null
                                                                                  approval pathway
                                                                                  Source null
                                                                                  biomarker and test
                                                                                  Source null
                                                                                  disease stage
                                                                                  Source null
                                                                                  limitations
                                                                                  Source null
                                                                                  line
                                                                                  Source null
                                                                                  prior therapy
                                                                                  Source null
                                                                                  regimen
                                                                                  Source null
                                                                                  tumor histology
                                                                                  Source null
                                                                                  use intent
                                                                                  unclear
                                                                                  Passage 18 · positive indication candidate
                                                                                  application numbers
                                                                                  1. BLA125057
                                                                                  brand names
                                                                                  1. Humira
                                                                                  classification reasons
                                                                                  1. explicit_positive_indication_predicate
                                                                                  2. no_tumor_directed_keyword_in_positive_statement
                                                                                  clinical review status
                                                                                  pending
                                                                                  content role
                                                                                  positive_indication_candidate
                                                                                  context span
                                                                                  end
                                                                                  2837
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  nhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. HUMIRA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HUMIRA is
                                                                                  label id
                                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                  start
                                                                                  2305
                                                                                  current approval status
                                                                                  not_reconciled
                                                                                  duplicate text group
                                                                                  dup-5b9339d2395daeb40af7
                                                                                  extraction review status
                                                                                  automated_candidate_pending_source_review
                                                                                  generic names
                                                                                  1. ADALIMUMAB
                                                                                  id
                                                                                  ind-span-d9352ed7fc7dfe5abbe1
                                                                                  label id
                                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                  positive predicate support span
                                                                                  end
                                                                                  2551
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  is indicated
                                                                                  label id
                                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                  start
                                                                                  2539
                                                                                  qualifier mentions
                                                                                  1. context exact
                                                                                    itis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
                                                                                    kind
                                                                                    age
                                                                                    polarity
                                                                                    not_inferred
                                                                                    span
                                                                                    end
                                                                                    2601
                                                                                    end exclusive
                                                                                    true
                                                                                    exact text
                                                                                    adult patients
                                                                                    label id
                                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                    offset unit
                                                                                    unicode_code_points
                                                                                    source array index
                                                                                    0
                                                                                    source field
                                                                                    indications_and_usage_exact
                                                                                    source text sha256
                                                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                    start
                                                                                    2587
                                                                                  regulatory links
                                                                                    schema version
                                                                                    0.1.0
                                                                                    source batch sha256
                                                                                    a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                    source defined aliases
                                                                                      source span
                                                                                      end
                                                                                      2637
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      1.4 Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
                                                                                      label id
                                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                      start
                                                                                      2505
                                                                                      source url
                                                                                      https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                      spl effective date
                                                                                      2025-12-23
                                                                                      spl set id
                                                                                      4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                      spl version
                                                                                      4
                                                                                      structured fields status
                                                                                      not_extracted_no_values_inferred_from_mentions
                                                                                      structured indication
                                                                                      age
                                                                                      Source null
                                                                                      approval pathway
                                                                                      Source null
                                                                                      biomarker and test
                                                                                      Source null
                                                                                      disease stage
                                                                                      Source null
                                                                                      limitations
                                                                                      Source null
                                                                                      line
                                                                                      Source null
                                                                                      prior therapy
                                                                                      Source null
                                                                                      regimen
                                                                                      Source null
                                                                                      tumor histology
                                                                                      Source null
                                                                                      use intent
                                                                                      non_oncology_or_unclear_candidate
                                                                                      Passage 19 · positive indication candidate
                                                                                      application numbers
                                                                                      1. BLA125057
                                                                                      brand names
                                                                                      1. Humira
                                                                                      classification reasons
                                                                                      1. explicit_positive_indication_predicate
                                                                                      2. no_tumor_directed_keyword_in_positive_statement
                                                                                      clinical review status
                                                                                      pending
                                                                                      content role
                                                                                      positive_indication_candidate
                                                                                      context span
                                                                                      end
                                                                                      3003
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      MIRA can be used alone or in combination with non-biologic DMARDs. 1.4 Ankylosing Spondylitis HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. 1.5 Crohn’s Disease HUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. Limitations of Use The effe
                                                                                      label id
                                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                      start
                                                                                      2438
                                                                                      current approval status
                                                                                      not_reconciled
                                                                                      duplicate text group
                                                                                      dup-75ec67723a5773569da0
                                                                                      extraction review status
                                                                                      automated_candidate_pending_source_review
                                                                                      generic names
                                                                                      1. ADALIMUMAB
                                                                                      id
                                                                                      ind-span-18c570bb5f500ffcdf10
                                                                                      label id
                                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                      positive predicate support span
                                                                                      end
                                                                                      2677
                                                                                      end exclusive
                                                                                      true
                                                                                      exact text
                                                                                      is indicated
                                                                                      label id
                                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                      offset unit
                                                                                      unicode_code_points
                                                                                      source array index
                                                                                      0
                                                                                      source field
                                                                                      indications_and_usage_exact
                                                                                      source text sha256
                                                                                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                      start
                                                                                      2665
                                                                                      qualifier mentions
                                                                                      1. context exact
                                                                                        eatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                                                                                        kind
                                                                                        age
                                                                                        polarity
                                                                                        not_inferred
                                                                                        span
                                                                                        end
                                                                                        2754
                                                                                        end exclusive
                                                                                        true
                                                                                        exact text
                                                                                        adults
                                                                                        label id
                                                                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                        offset unit
                                                                                        unicode_code_points
                                                                                        source array index
                                                                                        0
                                                                                        source field
                                                                                        indications_and_usage_exact
                                                                                        source text sha256
                                                                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                        start
                                                                                        2748
                                                                                      2. context exact
                                                                                        moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                                                                                        kind
                                                                                        age
                                                                                        polarity
                                                                                        not_inferred
                                                                                        span
                                                                                        end
                                                                                        2777
                                                                                        end exclusive
                                                                                        true
                                                                                        exact text
                                                                                        pediatric patients
                                                                                        label id
                                                                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                        offset unit
                                                                                        unicode_code_points
                                                                                        source array index
                                                                                        0
                                                                                        source field
                                                                                        indications_and_usage_exact
                                                                                        source text sha256
                                                                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                        start
                                                                                        2759
                                                                                      3. context exact
                                                                                        ely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                                                                                        kind
                                                                                        age
                                                                                        polarity
                                                                                        not_inferred
                                                                                        span
                                                                                        end
                                                                                        2792
                                                                                        end exclusive
                                                                                        true
                                                                                        exact text
                                                                                        6 years of age
                                                                                        label id
                                                                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                        offset unit
                                                                                        unicode_code_points
                                                                                        source array index
                                                                                        0
                                                                                        source field
                                                                                        indications_and_usage_exact
                                                                                        source text sha256
                                                                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                        start
                                                                                        2778
                                                                                      regulatory links
                                                                                        schema version
                                                                                        0.1.0
                                                                                        source batch sha256
                                                                                        a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                        source defined aliases
                                                                                          source span
                                                                                          end
                                                                                          2803
                                                                                          end exclusive
                                                                                          true
                                                                                          exact text
                                                                                          1.5 Crohn’s Disease HUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older.
                                                                                          label id
                                                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                          offset unit
                                                                                          unicode_code_points
                                                                                          source array index
                                                                                          0
                                                                                          source field
                                                                                          indications_and_usage_exact
                                                                                          source text sha256
                                                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                          start
                                                                                          2638
                                                                                          source url
                                                                                          https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                          spl effective date
                                                                                          2025-12-23
                                                                                          spl set id
                                                                                          4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                          spl version
                                                                                          4
                                                                                          structured fields status
                                                                                          not_extracted_no_values_inferred_from_mentions
                                                                                          structured indication
                                                                                          age
                                                                                          Source null
                                                                                          approval pathway
                                                                                          Source null
                                                                                          biomarker and test
                                                                                          Source null
                                                                                          disease stage
                                                                                          Source null
                                                                                          limitations
                                                                                          Source null
                                                                                          line
                                                                                          Source null
                                                                                          prior therapy
                                                                                          Source null
                                                                                          regimen
                                                                                          Source null
                                                                                          tumor histology
                                                                                          Source null
                                                                                          use intent
                                                                                          non_oncology_or_unclear_candidate
                                                                                          Passage 20 · positive indication candidate
                                                                                          application numbers
                                                                                          1. BLA125057
                                                                                          brand names
                                                                                          1. Humira
                                                                                          classification reasons
                                                                                          1. explicit_positive_indication_predicate
                                                                                          2. no_tumor_directed_keyword_in_positive_statement
                                                                                          clinical review status
                                                                                          pending
                                                                                          content role
                                                                                          positive_indication_candidate
                                                                                          context span
                                                                                          end
                                                                                          3175
                                                                                          end exclusive
                                                                                          true
                                                                                          exact text
                                                                                          th active ankylosing spondylitis. 1.5 Crohn’s Disease HUMIRA is indicated for the treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. 1.6 Ulcerative Colitis HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. Limitations of Use The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 , 14.8 ) ] . 1.7 Plaque P
                                                                                          label id
                                                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                          offset unit
                                                                                          unicode_code_points
                                                                                          source array index
                                                                                          0
                                                                                          source field
                                                                                          indications_and_usage_exact
                                                                                          source text sha256
                                                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                          start
                                                                                          2604
                                                                                          current approval status
                                                                                          not_reconciled
                                                                                          duplicate text group
                                                                                          dup-b894eecfbcf69abb9f5d
                                                                                          extraction review status
                                                                                          automated_candidate_pending_source_review
                                                                                          generic names
                                                                                          1. ADALIMUMAB
                                                                                          id
                                                                                          ind-span-52f65359a98a1b180aaa
                                                                                          label id
                                                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                          positive predicate support span
                                                                                          end
                                                                                          2846
                                                                                          end exclusive
                                                                                          true
                                                                                          exact text
                                                                                          is indicated
                                                                                          label id
                                                                                          5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                          offset unit
                                                                                          unicode_code_points
                                                                                          source array index
                                                                                          0
                                                                                          source field
                                                                                          indications_and_usage_exact
                                                                                          source text sha256
                                                                                          49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                          start
                                                                                          2834
                                                                                          qualifier mentions
                                                                                          1. context exact
                                                                                            ment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.
                                                                                            kind
                                                                                            age
                                                                                            polarity
                                                                                            not_inferred
                                                                                            span
                                                                                            end
                                                                                            2926
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            adults
                                                                                            label id
                                                                                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                            start
                                                                                            2920
                                                                                          2. context exact
                                                                                            erately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.
                                                                                            kind
                                                                                            age
                                                                                            polarity
                                                                                            not_inferred
                                                                                            span
                                                                                            end
                                                                                            2949
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            pediatric patients
                                                                                            label id
                                                                                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                            start
                                                                                            2931
                                                                                          3. context exact
                                                                                            active ulcerative colitis in adults and pediatric patients 5 years of age and older.
                                                                                            kind
                                                                                            age
                                                                                            polarity
                                                                                            not_inferred
                                                                                            span
                                                                                            end
                                                                                            2964
                                                                                            end exclusive
                                                                                            true
                                                                                            exact text
                                                                                            5 years of age
                                                                                            label id
                                                                                            5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                            offset unit
                                                                                            unicode_code_points
                                                                                            source array index
                                                                                            0
                                                                                            source field
                                                                                            indications_and_usage_exact
                                                                                            source text sha256
                                                                                            49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                            start
                                                                                            2950
                                                                                          regulatory links
                                                                                            schema version
                                                                                            0.1.0
                                                                                            source batch sha256
                                                                                            a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                            source defined aliases
                                                                                              source span
                                                                                              end
                                                                                              2975
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              1.6 Ulcerative Colitis HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older.
                                                                                              label id
                                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                              start
                                                                                              2804
                                                                                              source url
                                                                                              https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                              spl effective date
                                                                                              2025-12-23
                                                                                              spl set id
                                                                                              4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                              spl version
                                                                                              4
                                                                                              structured fields status
                                                                                              not_extracted_no_values_inferred_from_mentions
                                                                                              structured indication
                                                                                              age
                                                                                              Source null
                                                                                              approval pathway
                                                                                              Source null
                                                                                              biomarker and test
                                                                                              Source null
                                                                                              disease stage
                                                                                              Source null
                                                                                              limitations
                                                                                              Source null
                                                                                              line
                                                                                              Source null
                                                                                              prior therapy
                                                                                              Source null
                                                                                              regimen
                                                                                              Source null
                                                                                              tumor histology
                                                                                              Source null
                                                                                              use intent
                                                                                              non_oncology_or_unclear_candidate
                                                                                              Passage 21 · limitation of use
                                                                                              application numbers
                                                                                              1. BLA125057
                                                                                              brand names
                                                                                              1. Humira
                                                                                              classification reasons
                                                                                              1. negative_or_not_established_clause
                                                                                              clinical review status
                                                                                              pending
                                                                                              content role
                                                                                              limitation_of_use
                                                                                              context span
                                                                                              end
                                                                                              3362
                                                                                              end exclusive
                                                                                              true
                                                                                              exact text
                                                                                              s 6 years of age and older. 1.6 Ulcerative Colitis HUMIRA is indicated for the treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. Limitations of Use The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 , 14.8 ) ] . 1.7 Plaque Psoriasis HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other s
                                                                                              label id
                                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                              offset unit
                                                                                              unicode_code_points
                                                                                              source array index
                                                                                              0
                                                                                              source field
                                                                                              indications_and_usage_exact
                                                                                              source text sha256
                                                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                              start
                                                                                              2776
                                                                                              current approval status
                                                                                              not_reconciled
                                                                                              duplicate text group
                                                                                              dup-f43e9dd485acf552b809
                                                                                              extraction review status
                                                                                              automated_candidate_pending_source_review
                                                                                              generic names
                                                                                              1. ADALIMUMAB
                                                                                              id
                                                                                              ind-span-a4c023587b130639a8ff
                                                                                              label id
                                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                              positive predicate support span
                                                                                              Source null
                                                                                              qualifier mentions
                                                                                                regulatory links
                                                                                                  schema version
                                                                                                  0.1.0
                                                                                                  source batch sha256
                                                                                                  a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                                  source defined aliases
                                                                                                    source span
                                                                                                    end
                                                                                                    3162
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    Limitations of Use The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 , 14.8 ) ] .
                                                                                                    label id
                                                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                    start
                                                                                                    2976
                                                                                                    source url
                                                                                                    https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                                    spl effective date
                                                                                                    2025-12-23
                                                                                                    spl set id
                                                                                                    4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                                    spl version
                                                                                                    4
                                                                                                    structured fields status
                                                                                                    not_extracted_no_values_inferred_from_mentions
                                                                                                    structured indication
                                                                                                    age
                                                                                                    Source null
                                                                                                    approval pathway
                                                                                                    Source null
                                                                                                    biomarker and test
                                                                                                    Source null
                                                                                                    disease stage
                                                                                                    Source null
                                                                                                    limitations
                                                                                                    Source null
                                                                                                    line
                                                                                                    Source null
                                                                                                    prior therapy
                                                                                                    Source null
                                                                                                    regimen
                                                                                                    Source null
                                                                                                    tumor histology
                                                                                                    Source null
                                                                                                    use intent
                                                                                                    not_applicable
                                                                                                    Passage 22 · positive indication candidate
                                                                                                    application numbers
                                                                                                    1. BLA125057
                                                                                                    brand names
                                                                                                    1. Humira
                                                                                                    classification reasons
                                                                                                    1. explicit_positive_indication_predicate
                                                                                                    2. no_tumor_directed_keyword_in_positive_statement
                                                                                                    clinical review status
                                                                                                    pending
                                                                                                    content role
                                                                                                    positive_indication_candidate
                                                                                                    context span
                                                                                                    end
                                                                                                    3611
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    e and older. Limitations of Use The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers [see Clinical Studies ( 14.7 , 14.8 ) ] . 1.7 Plaque Psoriasis HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ] . 1.8 Hidradenitis Suppurativa HU
                                                                                                    label id
                                                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                    start
                                                                                                    2963
                                                                                                    current approval status
                                                                                                    not_reconciled
                                                                                                    duplicate text group
                                                                                                    dup-df61a545c0c5f351b79f
                                                                                                    extraction review status
                                                                                                    automated_candidate_pending_source_review
                                                                                                    generic names
                                                                                                    1. ADALIMUMAB
                                                                                                    id
                                                                                                    ind-span-16d0a5bfe8f460b93a8f
                                                                                                    label id
                                                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                    positive predicate support span
                                                                                                    end
                                                                                                    3203
                                                                                                    end exclusive
                                                                                                    true
                                                                                                    exact text
                                                                                                    is indicated
                                                                                                    label id
                                                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                    offset unit
                                                                                                    unicode_code_points
                                                                                                    source array index
                                                                                                    0
                                                                                                    source field
                                                                                                    indications_and_usage_exact
                                                                                                    source text sha256
                                                                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                    start
                                                                                                    3191
                                                                                                    qualifier mentions
                                                                                                    1. context exact
                                                                                                      7 Plaque Psoriasis HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are ca
                                                                                                      kind
                                                                                                      age
                                                                                                      polarity
                                                                                                      not_inferred
                                                                                                      span
                                                                                                      end
                                                                                                      3239
                                                                                                      end exclusive
                                                                                                      true
                                                                                                      exact text
                                                                                                      adult patients
                                                                                                      label id
                                                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                      offset unit
                                                                                                      unicode_code_points
                                                                                                      source array index
                                                                                                      0
                                                                                                      source field
                                                                                                      indications_and_usage_exact
                                                                                                      source text sha256
                                                                                                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                      start
                                                                                                      3225
                                                                                                    regulatory links
                                                                                                      schema version
                                                                                                      0.1.0
                                                                                                      source batch sha256
                                                                                                      a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                                      source defined aliases
                                                                                                        source span
                                                                                                        end
                                                                                                        3411
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        1.7 Plaque Psoriasis HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
                                                                                                        label id
                                                                                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                        start
                                                                                                        3163
                                                                                                        source url
                                                                                                        https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                                        spl effective date
                                                                                                        2025-12-23
                                                                                                        spl set id
                                                                                                        4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                                        spl version
                                                                                                        4
                                                                                                        structured fields status
                                                                                                        not_extracted_no_values_inferred_from_mentions
                                                                                                        structured indication
                                                                                                        age
                                                                                                        Source null
                                                                                                        approval pathway
                                                                                                        Source null
                                                                                                        biomarker and test
                                                                                                        Source null
                                                                                                        disease stage
                                                                                                        Source null
                                                                                                        limitations
                                                                                                        Source null
                                                                                                        line
                                                                                                        Source null
                                                                                                        prior therapy
                                                                                                        Source null
                                                                                                        regimen
                                                                                                        Source null
                                                                                                        tumor histology
                                                                                                        Source null
                                                                                                        use intent
                                                                                                        non_oncology_or_unclear_candidate
                                                                                                        Passage 23 · risk or warning
                                                                                                        application numbers
                                                                                                        1. BLA125057
                                                                                                        brand names
                                                                                                        1. Humira
                                                                                                        classification reasons
                                                                                                        1. risk_or_warning_words_without_positive_predicate
                                                                                                        clinical review status
                                                                                                        pending
                                                                                                        content role
                                                                                                        risk_or_warning
                                                                                                        context span
                                                                                                        end
                                                                                                        3779
                                                                                                        end exclusive
                                                                                                        true
                                                                                                        exact text
                                                                                                        treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ] . 1.8 Hidradenitis Suppurativa HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis HUMIRA is indicated for the treatm
                                                                                                        label id
                                                                                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                        offset unit
                                                                                                        unicode_code_points
                                                                                                        source array index
                                                                                                        0
                                                                                                        source field
                                                                                                        indications_and_usage_exact
                                                                                                        source text sha256
                                                                                                        49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                        start
                                                                                                        3212
                                                                                                        current approval status
                                                                                                        not_reconciled
                                                                                                        duplicate text group
                                                                                                        dup-752ef94662c66d40e55f
                                                                                                        extraction review status
                                                                                                        automated_candidate_pending_source_review
                                                                                                        generic names
                                                                                                        1. ADALIMUMAB
                                                                                                        id
                                                                                                        ind-span-01016de575ed64421cd8
                                                                                                        label id
                                                                                                        5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                        positive predicate support span
                                                                                                        Source null
                                                                                                        qualifier mentions
                                                                                                          regulatory links
                                                                                                            schema version
                                                                                                            0.1.0
                                                                                                            source batch sha256
                                                                                                            a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                                            source defined aliases
                                                                                                              source span
                                                                                                              end
                                                                                                              3579
                                                                                                              end exclusive
                                                                                                              true
                                                                                                              exact text
                                                                                                              HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ] .
                                                                                                              label id
                                                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                              offset unit
                                                                                                              unicode_code_points
                                                                                                              source array index
                                                                                                              0
                                                                                                              source field
                                                                                                              indications_and_usage_exact
                                                                                                              source text sha256
                                                                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                              start
                                                                                                              3412
                                                                                                              source url
                                                                                                              https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                                              spl effective date
                                                                                                              2025-12-23
                                                                                                              spl set id
                                                                                                              4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                                              spl version
                                                                                                              4
                                                                                                              structured fields status
                                                                                                              not_extracted_no_values_inferred_from_mentions
                                                                                                              structured indication
                                                                                                              age
                                                                                                              Source null
                                                                                                              approval pathway
                                                                                                              Source null
                                                                                                              biomarker and test
                                                                                                              Source null
                                                                                                              disease stage
                                                                                                              Source null
                                                                                                              limitations
                                                                                                              Source null
                                                                                                              line
                                                                                                              Source null
                                                                                                              prior therapy
                                                                                                              Source null
                                                                                                              regimen
                                                                                                              Source null
                                                                                                              tumor histology
                                                                                                              Source null
                                                                                                              use intent
                                                                                                              not_applicable
                                                                                                              Passage 24 · positive indication candidate
                                                                                                              application numbers
                                                                                                              1. BLA125057
                                                                                                              brand names
                                                                                                              1. Humira
                                                                                                              classification reasons
                                                                                                              1. explicit_positive_indication_predicate
                                                                                                              2. no_tumor_directed_keyword_in_positive_statement
                                                                                                              clinical review status
                                                                                                              pending
                                                                                                              content role
                                                                                                              positive_indication_candidate
                                                                                                              context span
                                                                                                              end
                                                                                                              3899
                                                                                                              end exclusive
                                                                                                              true
                                                                                                              exact text
                                                                                                              are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician [see Warnings and Precautions ( 5 ) ] . 1.8 Hidradenitis Suppurativa HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                              label id
                                                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                              offset unit
                                                                                                              unicode_code_points
                                                                                                              source array index
                                                                                                              0
                                                                                                              source field
                                                                                                              indications_and_usage_exact
                                                                                                              source text sha256
                                                                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                              start
                                                                                                              3380
                                                                                                              current approval status
                                                                                                              not_reconciled
                                                                                                              duplicate text group
                                                                                                              dup-3412f7195d15af0f80a7
                                                                                                              extraction review status
                                                                                                              automated_candidate_pending_source_review
                                                                                                              generic names
                                                                                                              1. ADALIMUMAB
                                                                                                              id
                                                                                                              ind-span-4bba5ccec0d439db1a1d
                                                                                                              label id
                                                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                              positive predicate support span
                                                                                                              end
                                                                                                              3628
                                                                                                              end exclusive
                                                                                                              true
                                                                                                              exact text
                                                                                                              is indicated
                                                                                                              label id
                                                                                                              5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                              offset unit
                                                                                                              unicode_code_points
                                                                                                              source array index
                                                                                                              0
                                                                                                              source field
                                                                                                              indications_and_usage_exact
                                                                                                              source text sha256
                                                                                                              49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                              start
                                                                                                              3616
                                                                                                              qualifier mentions
                                                                                                              1. context exact
                                                                                                                of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
                                                                                                                kind
                                                                                                                age
                                                                                                                polarity
                                                                                                                not_inferred
                                                                                                                span
                                                                                                                end
                                                                                                                3721
                                                                                                                end exclusive
                                                                                                                true
                                                                                                                exact text
                                                                                                                12 years of age
                                                                                                                label id
                                                                                                                5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                offset unit
                                                                                                                unicode_code_points
                                                                                                                source array index
                                                                                                                0
                                                                                                                source field
                                                                                                                indications_and_usage_exact
                                                                                                                source text sha256
                                                                                                                49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                                start
                                                                                                                3706
                                                                                                              regulatory links
                                                                                                                schema version
                                                                                                                0.1.0
                                                                                                                source batch sha256
                                                                                                                a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                                                source defined aliases
                                                                                                                  source span
                                                                                                                  end
                                                                                                                  3732
                                                                                                                  end exclusive
                                                                                                                  true
                                                                                                                  exact text
                                                                                                                  1.8 Hidradenitis Suppurativa HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
                                                                                                                  label id
                                                                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                  offset unit
                                                                                                                  unicode_code_points
                                                                                                                  source array index
                                                                                                                  0
                                                                                                                  source field
                                                                                                                  indications_and_usage_exact
                                                                                                                  source text sha256
                                                                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                                  start
                                                                                                                  3580
                                                                                                                  source url
                                                                                                                  https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                                                  spl effective date
                                                                                                                  2025-12-23
                                                                                                                  spl set id
                                                                                                                  4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                                                  spl version
                                                                                                                  4
                                                                                                                  structured fields status
                                                                                                                  not_extracted_no_values_inferred_from_mentions
                                                                                                                  structured indication
                                                                                                                  age
                                                                                                                  Source null
                                                                                                                  approval pathway
                                                                                                                  Source null
                                                                                                                  biomarker and test
                                                                                                                  Source null
                                                                                                                  disease stage
                                                                                                                  Source null
                                                                                                                  limitations
                                                                                                                  Source null
                                                                                                                  line
                                                                                                                  Source null
                                                                                                                  prior therapy
                                                                                                                  Source null
                                                                                                                  regimen
                                                                                                                  Source null
                                                                                                                  tumor histology
                                                                                                                  Source null
                                                                                                                  use intent
                                                                                                                  non_oncology_or_unclear_candidate
                                                                                                                  Passage 25 · positive indication candidate
                                                                                                                  application numbers
                                                                                                                  1. BLA125057
                                                                                                                  brand names
                                                                                                                  1. Humira
                                                                                                                  classification reasons
                                                                                                                  1. explicit_positive_indication_predicate
                                                                                                                  2. no_tumor_directed_keyword_in_positive_statement
                                                                                                                  clinical review status
                                                                                                                  pending
                                                                                                                  content role
                                                                                                                  positive_indication_candidate
                                                                                                                  context span
                                                                                                                  end
                                                                                                                  3899
                                                                                                                  end exclusive
                                                                                                                  true
                                                                                                                  exact text
                                                                                                                  sician [see Warnings and Precautions ( 5 ) ] . 1.8 Hidradenitis Suppurativa HUMIRA is indicated for the treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older. 1.9 Uveitis HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                                  label id
                                                                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                  offset unit
                                                                                                                  unicode_code_points
                                                                                                                  source array index
                                                                                                                  0
                                                                                                                  source field
                                                                                                                  indications_and_usage_exact
                                                                                                                  source text sha256
                                                                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                                  start
                                                                                                                  3533
                                                                                                                  current approval status
                                                                                                                  not_reconciled
                                                                                                                  duplicate text group
                                                                                                                  dup-0159cee930c22a0076be
                                                                                                                  extraction review status
                                                                                                                  automated_candidate_pending_source_review
                                                                                                                  generic names
                                                                                                                  1. ADALIMUMAB
                                                                                                                  id
                                                                                                                  ind-span-340b60d69058cbcd5106
                                                                                                                  label id
                                                                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                  positive predicate support span
                                                                                                                  end
                                                                                                                  3764
                                                                                                                  end exclusive
                                                                                                                  true
                                                                                                                  exact text
                                                                                                                  is indicated
                                                                                                                  label id
                                                                                                                  5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                  offset unit
                                                                                                                  unicode_code_points
                                                                                                                  source array index
                                                                                                                  0
                                                                                                                  source field
                                                                                                                  indications_and_usage_exact
                                                                                                                  source text sha256
                                                                                                                  49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                                  start
                                                                                                                  3752
                                                                                                                  qualifier mentions
                                                                                                                  1. context exact
                                                                                                                    f non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                                    kind
                                                                                                                    age
                                                                                                                    polarity
                                                                                                                    not_inferred
                                                                                                                    span
                                                                                                                    end
                                                                                                                    3850
                                                                                                                    end exclusive
                                                                                                                    true
                                                                                                                    exact text
                                                                                                                    adults
                                                                                                                    label id
                                                                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                    offset unit
                                                                                                                    unicode_code_points
                                                                                                                    source array index
                                                                                                                    0
                                                                                                                    source field
                                                                                                                    indications_and_usage_exact
                                                                                                                    source text sha256
                                                                                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                                    start
                                                                                                                    3844
                                                                                                                  2. context exact
                                                                                                                    tious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                                    kind
                                                                                                                    age
                                                                                                                    polarity
                                                                                                                    not_inferred
                                                                                                                    span
                                                                                                                    end
                                                                                                                    3873
                                                                                                                    end exclusive
                                                                                                                    true
                                                                                                                    exact text
                                                                                                                    pediatric patients
                                                                                                                    label id
                                                                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                    offset unit
                                                                                                                    unicode_code_points
                                                                                                                    source array index
                                                                                                                    0
                                                                                                                    source field
                                                                                                                    indications_and_usage_exact
                                                                                                                    source text sha256
                                                                                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                                    start
                                                                                                                    3855
                                                                                                                  3. context exact
                                                                                                                    posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                                    kind
                                                                                                                    age
                                                                                                                    polarity
                                                                                                                    not_inferred
                                                                                                                    span
                                                                                                                    end
                                                                                                                    3888
                                                                                                                    end exclusive
                                                                                                                    true
                                                                                                                    exact text
                                                                                                                    2 years of age
                                                                                                                    label id
                                                                                                                    5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                    offset unit
                                                                                                                    unicode_code_points
                                                                                                                    source array index
                                                                                                                    0
                                                                                                                    source field
                                                                                                                    indications_and_usage_exact
                                                                                                                    source text sha256
                                                                                                                    49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                                    start
                                                                                                                    3874
                                                                                                                  regulatory links
                                                                                                                    schema version
                                                                                                                    0.1.0
                                                                                                                    source batch sha256
                                                                                                                    a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
                                                                                                                    source defined aliases
                                                                                                                      source span
                                                                                                                      end
                                                                                                                      3899
                                                                                                                      end exclusive
                                                                                                                      true
                                                                                                                      exact text
                                                                                                                      1.9 Uveitis HUMIRA is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.
                                                                                                                      label id
                                                                                                                      5fe81b1a-cc31-444e-a0f1-1ea4f7334b89
                                                                                                                      offset unit
                                                                                                                      unicode_code_points
                                                                                                                      source array index
                                                                                                                      0
                                                                                                                      source field
                                                                                                                      indications_and_usage_exact
                                                                                                                      source text sha256
                                                                                                                      49e4547253cfa2952bb42e62f99a677f4bd34546ac298c77ebc21f30fdbc76b9
                                                                                                                      start
                                                                                                                      3733
                                                                                                                      source url
                                                                                                                      https://api.fda.gov/drug/label.json?search=id%3A%225fe81b1a-cc31-444e-a0f1-1ea4f7334b89%22
                                                                                                                      spl effective date
                                                                                                                      2025-12-23
                                                                                                                      spl set id
                                                                                                                      4977567e-3525-44ac-9ff5-f1e74b053950
                                                                                                                      spl version
                                                                                                                      4
                                                                                                                      structured fields status
                                                                                                                      not_extracted_no_values_inferred_from_mentions
                                                                                                                      structured indication
                                                                                                                      age
                                                                                                                      Source null
                                                                                                                      approval pathway
                                                                                                                      Source null
                                                                                                                      biomarker and test
                                                                                                                      Source null
                                                                                                                      disease stage
                                                                                                                      Source null
                                                                                                                      limitations
                                                                                                                      Source null
                                                                                                                      line
                                                                                                                      Source null
                                                                                                                      prior therapy
                                                                                                                      Source null
                                                                                                                      regimen
                                                                                                                      Source null
                                                                                                                      tumor histology
                                                                                                                      Source null
                                                                                                                      use intent
                                                                                                                      non_oncology_or_unclear_candidate

                                                                                                                      Preserved source evidence · Not medical advice